深圳市亦诺微医药科技有限公司 Immvira Co. Ltd
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
High Response in Bladder Cancer: Immvira Announced Its MVR-T3011 Latest Clinical Results in BCG-Unresponsive Bladder Cancer Patients at 2025 Annual Meeting of the Society of Urologic Oncology 2025-12-04 08:00
ImmVira Announces First-in-Human Data of Engineered Exosome MVR-EX105 for Fat Reduction and Muscle Preservation by Topical Application at 2025 Annual Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders 2025-09-10 10:49
World's First Engineered Exosome for Hair Growth & Localized Fat Reduction Secure INCI Designation: ImmVira Accelerates Access to Billion-Dollar Aging-related Market 2025-07-28 20:28
ImmVira Announces First Patient Dosed in a Multi-Regional Phase II Clinical Trial Evaluating MVR-T3011 Oncolytic Immunotherapy in Patients with BCG-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) 2025-06-10 20:00
ImmVira Presented Clinical Results of Oncolytic Product MVR-C5252 Targeting Malignant Glioma via Convection-Enhanced Delivery at 2025 AACR Annual Meeting 2025-04-28 09:00
Global First Engineered Exosome with INCI Name -- ImmVira Leads a New Era in International Cosmetic Ingredients 2025-04-11 13:19
ESMO 2024 - ImmVira Unveils Clinical Results of Intravesical MVR-T3011 for High-Risk BCG-Failure NMIBC Patients 2024-09-15 17:53
ImmVira's oncolytic product MVR-T3011 IT Intratumoral Injection Receives FDA Fast Track Designation for HNSCC Treatment 2024-03-15 13:56
MVR-T3011 IV, Global First Intravenous Oncolytic Product, Successfully Concludes Phase I Clinical Study in the U.S. with Outstanding Safety Results 2023-11-10 08:00
ImmVira Appoints Howard L. Kaufman, M.D. as Consulting Medical Advisor 2023-08-23 10:51
ImmVira presented latest encouraging clinical results of two proprietary products at ASCO 2023 2023-06-07 08:00
ImmVira Appoints Dr. Oliver Kong as Chief Medical Officer 2023-04-21 09:06
AACR 2023 | ImmVira presented preclinical study results of first CAR-T enabler oncolytic product MVR-T7011 at AACR Annual Meeting 2023-04-19 08:29
ImmVira's oncolytic product MVR-C5252 targeting malignant glioma obtained NMPA's approval for Clinical Trial in China 2023-03-30 08:00
ImmVira Clinical Snapshot: Intratumoral Injected OV (MVR-T3011 IT) Monotherapy Achieved Median PFS of 12.9 Months on Treatment of Melanoma 2023-02-09 08:00
ImmVira announced its signing of Series C+ financing and negotiation with further investors for the round 2022-10-26 14:26
ImmVira announced to launch the construction of Global R&D and Commercialization Base 2022-10-18 16:22
ImmVira's Brand New oHSV Product MVR-C5252 Targeting Malignant Glioma Obtained FDA's Orphan Drug Designation 2022-08-08 08:30
ImmVira's intravenous administered oHSV MVR-T3011 IV demonstrated promising clinical biological activities 2022-07-21 08:00
ImmVira enters clinical development in combination therapy of MVR-T3011 IT and MEK inhibitor in the U.S. 2022-04-20 08:00
1 2